Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.

2.50
Hdl Handle:
http://hdl.handle.net/10147/146583
Title:
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
Authors:
Hogan, A E; Tobin, A M; Ahern, T; Corrigan, M A; Gaoatswe, G; Jackson, R; O'Reilly, V; Lynch, L; Doherty, D G; Moynagh, P N; Kirby, B; O'Connell, J; O'Shea, D
Affiliation:
Department of Endocrinology, St Vincent's University Hospital, University College Dublin, Dublin 4, Ireland.
Citation:
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. 2011, 54 (11):2745-54 Diabetologia
Journal:
Diabetologia
Issue Date:
Nov-2011
URI:
http://hdl.handle.net/10147/146583
DOI:
10.1007/s00125-011-2232-3
PubMed ID:
21744074
Abstract:
The innate immune cells, invariant natural killer T cells (iNKT cells), are implicated in the pathogenesis of psoriasis, an inflammatory condition associated with obesity and other metabolic diseases, such as diabetes and dyslipidaemia. We observed an improvement in psoriasis severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor agonist. This was independent of change in glycaemic control. We proposed that this unexpected clinical outcome resulted from a direct effect of GLP-1 on iNKT cells.; We measured circulating and psoriatic plaque iNKT cell numbers in two patients with type 2 diabetes and psoriasis before and after commencing GLP-1 analogue therapy. In addition, we investigated the in vitro effects of GLP-1 on iNKT cells and looked for a functional GLP-1 receptor on these cells.; The Psoriasis Area and Severity Index improved in both patients following 6 weeks of GLP-1 analogue therapy. This was associated with an alteration in iNKT cell number, with an increased number in the circulation and a decreased number in psoriatic plaques. The GLP-1 receptor was expressed on iNKT cells, and GLP-1 induced a dose-dependent inhibition of iNKT cell cytokine secretion, but not cytolytic degranulation in vitro.; The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.
Item Type:
Article
Language:
en
ISSN:
1432-0428

Full metadata record

DC FieldValue Language
dc.contributor.authorHogan, A Een
dc.contributor.authorTobin, A Men
dc.contributor.authorAhern, Ten
dc.contributor.authorCorrigan, M Aen
dc.contributor.authorGaoatswe, Gen
dc.contributor.authorJackson, Ren
dc.contributor.authorO'Reilly, Ven
dc.contributor.authorLynch, Len
dc.contributor.authorDoherty, D Gen
dc.contributor.authorMoynagh, P Nen
dc.contributor.authorKirby, Ben
dc.contributor.authorO'Connell, Jen
dc.contributor.authorO'Shea, Den
dc.date.accessioned2011-10-24T15:17:25Z-
dc.date.available2011-10-24T15:17:25Z-
dc.date.issued2011-11-
dc.identifier.citationGlucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. 2011, 54 (11):2745-54 Diabetologiaen
dc.identifier.issn1432-0428-
dc.identifier.pmid21744074-
dc.identifier.doi10.1007/s00125-011-2232-3-
dc.identifier.urihttp://hdl.handle.net/10147/146583-
dc.description.abstractThe innate immune cells, invariant natural killer T cells (iNKT cells), are implicated in the pathogenesis of psoriasis, an inflammatory condition associated with obesity and other metabolic diseases, such as diabetes and dyslipidaemia. We observed an improvement in psoriasis severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor agonist. This was independent of change in glycaemic control. We proposed that this unexpected clinical outcome resulted from a direct effect of GLP-1 on iNKT cells.-
dc.description.abstractWe measured circulating and psoriatic plaque iNKT cell numbers in two patients with type 2 diabetes and psoriasis before and after commencing GLP-1 analogue therapy. In addition, we investigated the in vitro effects of GLP-1 on iNKT cells and looked for a functional GLP-1 receptor on these cells.-
dc.description.abstractThe Psoriasis Area and Severity Index improved in both patients following 6 weeks of GLP-1 analogue therapy. This was associated with an alteration in iNKT cell number, with an increased number in the circulation and a decreased number in psoriatic plaques. The GLP-1 receptor was expressed on iNKT cells, and GLP-1 induced a dose-dependent inhibition of iNKT cell cytokine secretion, but not cytolytic degranulation in vitro.-
dc.description.abstractThe clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.-
dc.language.isoenen
dc.titleGlucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, St Vincent's University Hospital, University College Dublin, Dublin 4, Ireland.en
dc.identifier.journalDiabetologiaen
dc.description.provinceLeinster-
All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.